People · Operator
Named in public records as an officer, director or promoter · active 2019–2023 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Verseon Corp | — | Pharmaceuticals | Series A | $24.9M | $3.1M | 2019 |
| Encentrio Therapeutics, Inc. | — | Biotechnology | Pre-Seed | $400K | $4.1M | 2023 |
Thomas Hecht at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas Hecht on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| George Scangos | 1 | 4 |
| Sung Lee | 1 | 2 |
| Eniko Fodor | 1 | 1 |
| Johanna Friedl-Naderer | 1 | 1 |
| Natascha Schill | 1 | 1 |
| Vanina De Verneuil | 1 | 1 |
| Adityo Prakash | 1 | 1 |
| Sangtae Kim | 1 | 1 |
| David Kita | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.